bioRxiv / medRxiv
open access
Safety and Biological Activity of Intravitreal OGX110, a CXCR3 Agonist, in Persistent Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ranibizumab Plus Indomethacin#1164498
- Phase II Study of ZD6474 in Advanced NSCLC#1101898
- Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.#884628
- Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD#849022
- SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration#862408
Record · ID 319799
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive